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 ABSTRACT 
PC4 and SFRS1 interacting protein 1 (PSIP1) encodes two splice variants, lens epithelium-
derived growth factor or p75 (LEDGF/p75) and p52. PSIP1 gene products were shown to be 
involved in transcriptional regulation, affecting a plethora of cellular processes, including cell 
proliferation, cell survival, and stress response. Furthermore, LEDGF/p75 has implications for 
various diseases and infections, including autoimmunity, leukemia, embryo development, 
psoriasis and HIV integration. Here, we reported the first characterization of the 
PSIP1promoter. By 5’ RACE approach, we identified novel transcription start sites in 
different cell types. Using a luciferase reporter system, we identified regulatory elements 
controlling LEDGF/p75 and p52 expression. These include i) minimal promoters, -112/+59 
and +609/+781, driving the basal expression of LEDGF/p75 and the shorter splice variant p52 
respectively, ii) a sequence (+319/+397) that may control the ratio between LEDGF/p75 and 
p52 expression, and iii) a strong enhancer (-320/-207) implicated in the modulation of 
LEDGF/p75 transcriptional activity. Computational, biochemical and genetic approaches 
enabled to identify the transcription factor Sp1 as a key modulator of the PSIP1 promoter, 
controlling LEDGF/p75 transcription through two binding sites at -72/-64 and -46/-36.  
Overall, our results provide the first data concerning the LEDGF/p75 promoter regulation 
giving new insights to further understand its biological function as well as opening the door of 
new therapeutic strategies in which LEDGF/p75 is involved. 
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 INTRODUCTION 
Lens epithelium-derived growth factor or p75 (LEDGF/p75) and its shorter form p52 are two 
ubiquitously expressed splice variants encoded by the PSIP1 gene (PC4 and SFRS1 
interacting protein 1) (Figure 1a), highly expressed in thymus, testis and brain, with 
LEDGF/p75 being the most abundant splice variant 1. They were initially identified through 
cofractionation with the transcriptional positive co-activator PC4 from HeLa cell extracts 1. 
As PC4, both LEDGF/p75 and p52 proteins were shown in vitro to be co-activators of the 
general transcriptional machinery, significantly enhancing transcription although with 
different intensities 2.  
LEDGF/p75 and p52 share the same first 325 amino acids, mostly involved in chromatin 
association. This N-terminal region contains a conserved PWWP domain, two AT-hook 
motifs, three charged regions (CR) and a classical nuclear localization signal (NLS) (Figure 
1a) 3; 4. In contrast, the C-terminal portion of the two PSIP1 gene products is different, thereby 
contributing to divergent specificities for interacting with different protein partners. Apart 
from its co-activator role, little is known about p52 1. Recent findings suggested that p52 
overexpression was able to promote apoptosis in cancer cells 5, and to favor neurite growth 
and axonal elongation in neural cells 6.  
In contrast, the second splice variant LEDGF/p75 has been more thoroughly investigated, 
however cellular roles of this protein are still incompletely characterized. LEDGF/p75 was 
described as a growth factor,  a transcriptional co-activator, and a chromatin adapter, with 
implications in cell survival under stress-related conditions, homeobox gene regulation, 
autoimmunity, leukemia transformation, psoriasis pathology, and integration of the human 
immunodeficiency virus (HIV) DNA in the host genome 7; 8; 9; 10; 11; 12; 13; 14; 15. These disparate 
cellular effects may reflect the variety of interacting protein partners. To date, these include 
JPO2/RAM2 protein 16; 17, the pogo transposable element with ZNF domain (pogZ) 18, 
 
 menin/MLL complex 15 and the Cdc7-activator of S-phase kinase (ASK) 19. All these proteins 
bind specifically to the C-terminal domain of LEDGF/p75 that helps their recruitment to the 
chromosome, thereby implying a role for LEDGF/p75 as a general adaptor protein tethering 
diverse factors to chromatin. To date, among LEGDF/p75 interacting proteins, the one 
between LEDGF/p75 and the HIV integrase protein is the best characterized 20; 21; 22; 23; 24. 
Upon entry into the host cell, HIV RNA genome is reverse transcribed into a linear double 
stranded DNA, which is subsequently imported into the nucleus and integrated into the 
genome of the host cell by the virally encoded integrase. The sites of HIV integration events 
are not random but display preferences for active transcription units 22. The current model 
suggests that the chromatin-associated LEDGF/p75 recruits the incoming HIV preintegration 
complexes by direct binding to the viral integrase, thereby promoting integration to nearby 
genomic locations 25; 26; 27; 28. 
Despite the increased interest in understanding the biological roles of LEDGF/p75 and p52, 
little is known about their expression regulation. Recently, Brown-Bryan et al showed that 
LEDGF/p75 and its shorter splice variant p52 are overexpressed, in tumor cells 5. It has been 
proposed that LEDGF/p75 and p52 relative amounts could influence survival and cell death 
decisions under stress. Indeed, stress-related conditions, including serum starvation, oxidative 
stress, tumor necrosis factor alpha (TNF-α), heat shock and UV irradiation were shown to 
stimulate LEDGF/p75 expression, thereby improving survival of a wide range of cells types 
29; 30. The opposite effect has been observed in transforming growth factor β (TGF-β)-treated 
cells reducing LEDGF/p75 mRNA expression and stress-related LEDGF/p75 downstream 
genes 31. In contrast to LEDGF/p75, overexpression of p52 induced apoptosis, and caspase-
mediated cleavage of p52 generates a shorter fragment that interferes with the transactivation 
potential of the survival LEDGF/p75 protein in various tumor cell lines 5. Understanding 
expression of PSIP1 splice variants may help modulating the fate of cancer cells, either 
 
 survival or death, and therefore may provide attractive strategies to overcome tumor 
chemoresistance as well as reducing the tumorigenic potential of LEDGF/p75-overexpressing 
cells 10; 11; 32.  
In the present study, PSIP1 promoter truncations cloned in a luciferase reporter system were 
used to uncover key genomic regions involved in LEDGF/p75 expression. These include the 
identification of LEDGF/p75 and p52 minimal promoters, as well as cis-acting regions 
including the +319/+397 region potentially controlling LEDGF/p75 and p52 expression ratio. 
Computational and experimental analyses identified the transcription factor Sp1 as a key 
player modulating LEDGF/p75 expression. Understanding LEDGF/p75 expression regulation 
may help to characterize the biological function of LEDGF/p75 and provide attractive 
strategies for LEDGF/p75-related pathologies. 
 
 RESULTS 
 
Identification of novel transcriptional start sites for LEDGF/p75 and p52. 
According to the NCBI sequence database, the PSIP1 promoter contains two transcription 
start sites (TSS), presumably one for each PSIP1 splice variant, LEDGF/p75 and p52 (Figure 
1a). TSS positions for LEDGF/p75 (NM_033222.3 and NM_001128217.1; NCBI) and p52 
(NM_021144.3; NCBI) transcripts were initially determined by Ge and collaborators 1 and 
subsequently modified by the NCBI staff and collaborators upon further bioinformatic 
analyses. In addition to these reference transcripts, multiple alternative splice variants were 
reported, starting at various TSSs.  
To characterize the TSS of PSIP1 splice variants in our experimental system, i.e. in HEK 
cells, we used a 5’- RNA Ligase Mediated Rapid Amplification of cDNA Ends (5’-RLM-
RACE) approach. PSIP1 mRNAs were successfully amplified using specific primers (Table 1 
and Figure 1b) located at the beginning of the coding sequence. Upon 5’ end sequence 
analysis of 26 PSIP1-specific transcripts, we identified LEDGF/p75 TSS in our system 
(Figure 1c, +1), 36 bp downstream of the previously reported reference variant 3 
(NM_001128217.1) (Figure 1c, black triangle), as well as the p52 TSS (Figure 1c, +745), 64 
bp downstream of the previously reported reference variant (NM_021144.3) (Figure 1c, black 
triangle).  
We also identified some minor TSSs (Figure 1c, arrows) indicating that, for both spliced 
variants, some sloppiness of the transcription initiation can occur. A similar 5’-RLM-RACE 
experiment was performed in SupT1 cells (T-cell line) and sequence analysis of 92 PSIP1 
transcripts confirmed the TSS positions determined previously in HEK cells. 
 
 Based on these data, we used the LEDGF/p75 5’end position newly identified in our 
experimental conditions as the major TSS reference, designated +1 (Figure 1c). Compared to 
this, p52 TSS corresponds to +745, and the ATG start codon of the coding sequence to +782. 
Analysis of transcripts starting at +1 in HEK and SupT1 cells confirmed the presence of an 
intron (+154/+640) consistent with the one described in LEDGF/p75 transcripts 
(NM_001128217.1), (Figure 1c) 1.  
In order to investigate the possible existence of endogenous LEDGF/p75 and p52 alternative 
transcripts starting at both TSSs, we performed reverse transcription using 3’ primers specific 
for each transcript (Figure 1d). LEDGF/p75 specific transcripts were amplified by PCR using 
a primer close to the LEDGF/p75 TSS (Figure 1d, lane 1), while p52 specific transcripts were 
not (Figure 1d, lane 3), suggesting that in these conditions, no p52 transcript starting at the 
LEDGF/p75 TSS was detected, arguing for TSS-specific transcripts. As control, PCR 
amplification from the ATG to the transcript specific 3’ end was also performed (Figure 1d, 
lanes 2 and 4). 
All together, these experiments suggest that the position of the TSS determines the nature of 
the splice variant. 
 
Identification of the PSIP1 functional promoter.  
To uncover essential regions in PSIP1 promoter sequence, we cloned PSIP1 promoter 
truncations upstream of a firefly luciferase reporter gene. Promoter activity was assessed by 
luciferase expression in HEK cells. We first used the PSIP1 promoter sequence ranging from 
-2043 to +781 (Figure 2a), thus containing both LEDGF/p75 and p52 TSSs, as well as the 
intron (+154/+640). Using luciferase-specific primers for 5’-RLM-RACE, we analyzed 49 
clones. 32 clones identified a TSS at position +745 (with minor sloppiness), corresponding to 
the endogenous p52 TSS, and 17 clones identified a TSS at position +1 consistent with the 
 
 endogenous LEDGF/p75 TSS. Luciferase transcripts starting at LEDGF/p75 TSS revealed the 
absence of the +154/+640 sequence, consistent with intron splicing. No additional minor TSS 
was identified when using PSIP1-driven luciferase constructs. These data suggested that 
PSIP1-firefly luciferase constructs transfected in HEK cells recapitulated PSIP1 endogenous 
transcriptional activity and alternative splicing, validating our experimental approach for 
subsequent analysis of PSIP1 promoter activity by luciferase reporter assay.  
Luciferase expression driven by PSIP1 -2043/+781 promoter resulted in ~98x activity above 
background (Figure 2b and supplementary figure S1). Progressive PSIP1 promoter 
truncations revealed that deleting sequences between -2043 and -723 did not affect 
significantly luciferase expression, as the PSIP1 -723/+781 promoter construct showed a 
luciferase activity similar to the -2043/+781 one (Figure 2b and supplementary figure S1). In 
contrast, PSIP1 -207/+781 promoter construct showed a luciferase activity of ~25x above 
background, a 4-fold reduction as compared to the -723/+781 construct (p <0.01) (Figure 2b 
and supplementary figure S1), suggesting that the -723/+781 sequence contained the major 
determinants of the functional PSIP1 promoter, and that the -723/-207 region may contain an 
enhancer.  
 
LEDGF/p75 promoter activity is higher than p52 promoter activity. 
 To determine separately the expression of the two PSIP1 splice variants and the minimal 
promoters driving their transcription, the -723/+781 fragment was split into two smaller 
fragments: -723/+59 and +140/+781 containing the LEDGF/p75 TSS and the p52 TSS 
respectively (Figure 2c and supplementary figure S1). Measurement of their respective 
luciferase activities revealed that promoter activity of the -723/+781 fragment was ~67x 
above background, while -723/+59 and +140/+781 displayed activities of 59x and 5x above 
background respectively, suggesting that PSIP1 -723/+781 resulted from the additive 
 
 transcriptional activities initiated at each TSS. In addition, -723/+59 containing the 
LEDGF/p75 TSS was ~12 fold more efficient than the p52 TSS-containing +140/+781 region 
in driving luciferase expression, consistent with higher expression of LEDGF/p75 compared 
to p52 observed in vivo 5.  
 
Identification of the LEDGF/p75 minimal promoter (-112/+59) and an enhancer region 
(-320/-207).  
To identify regulatory elements driving LEDGF/p75 expression, finer progressive 5’deletions 
of the -723/+59 promoter fragment (containing only the TSS of LEDGF/p75) were generated 
and tested for luciferase activity (Figure 2d). Luciferase activity was similar in promoter 
constructs carrying progressive 5’deletions from -723 to -320, indicating that the -723/-320 
fragment did not contain major regulatory elements. In contrast, the luciferase activity of the 
fragment -207/+59 strongly decreased (~2.5 fold, p value ≤ 0.01), consistent with the presence 
of a putative enhancer in the -320/-207 region. 
A second drop in luciferase activity was observed with the -37/+59 construct below the 
threshold of detectable luciferase activity (1.5x above background, p value ≤ 0.001) as 
compared to the -112/+59 construct, suggesting that the -112/+59 fragment contained the 
minimal determinants required for LEDGF/p75 expression (Figure 2d, left panel). To further 
assess the role of the -112/+59 region, this region was deleted in the -320/+781 construct and 
tested for luciferase activity (supplementary figure S1). Deletion of this region totally 
abrogated LEDGF/p75 expression without affecting p52 expression (supplementary figure 
S1). 
To validate the -320/-207 region as a functional enhancer, the -320/-207 fragment was cloned 
upstream a consensual TATA-box driving the expression of firefly luciferase (pGL4.23 
vector) and compared the luciferase activity in presence or in absence of the enhancer (Figure 
 
 2d, right panel). Luciferase activity driven by a minimal promoter and the -320/-207 fragment 
was ~23 fold higher than the one driven by the minimal promoter only pGL4.23, p < 0.001), 
confirming that the -320/-207 region contained a functional enhancer.  
 
Identification of regulatory elements in p52 promoter.  
The luciferase activity driven by the PSIP1 +140/+781 was 5x above background (Figure 2e). 
Progressive 5’deletions from +140 to +448 of the region containing p52 TSS showed similar 
levels of luciferase activity, suggesting that this region did not contain major determinants 
regulating p52 expression. However, deletion of the region +448/+548 and +548/+609 
induced a moderate but significant decrease in luciferase activity (p value ≤ 0.01), suggesting 
that the region +448/+609 contained regulatory elements enhancing the transcription from 
p52 TSS (figure 2e). Although the luciferase activity driven by regions surrounding the p52 
TSS was low, the +609/+781 region exhibited a low but significant activity (~1.7 fold 
expression above background, p value ≤ 0.001), indicative of the p52 minimal promoter. 
 
Crosstalk between LEDGF/p75 and p52 promoter activities. 
Independent analysis of LEDGF/p75 and p52 promoters revealed the presence of regulatory 
elements affecting the expression of each splice variant. However, in vivo, these two 
promoters overlap and may interfere with one another, probably leading to the observed 
difference between LEDGF/p75 and p52 expression. To investigate this possibility, we 
analyzed luciferase activity driven by various LEDGF/p75 promoter constructs (Figure 3). 
We first assessed the luciferase activity of constructs starting from -320 with progressive 3’ 
deletions (Figure 3, top panel). Luciferase activity driven by the LEDGF/p75 TSS was not 
reproducibly different between promoter constructs ranging from -320/+59 to -320/+339. In 
contrast, the presence of the +339/+420 region strongly reduced luciferase activity up to 
 
 background level (Figure 3, top panel, construct -320/+420), suggesting that this region had a 
strong silencer activity on LEDGF/p75 TSS. Addition of region +521/+659 abolished the 
+339/+420 silencer effect and enhanced the overall luciferase activity of ~2 fold as compared 
to -320/+59 constructs, suggesting a dominant effect of this enhancer (Figure 3, top  panel, 
construct -320/+659). Finally, the -320/+781 construct, containing both LEDGF/p75 and p52 
TSS showed a reduced luciferase activity as compared to the -320/+659 construct, but a 
similar activity as compared to the -320/+59 construct (Figure 3, top panel), suggesting that 
the +659/+781 region inhibits the enhancer effect of the +521/+659 region. 
We then assessed the luciferase activity of similar constructs but starting at -207, thus without 
the -320/-207 enhancer region (Figure 3, middle panel). The profile of luciferase activity were 
similar to the -320 constructs but at lower levels of activity (~2.5 fold reduction) due to the 
absence of the -320/-207 enhancer region defined previously. 
The luciferase activity of constructs starting at -112 (Figure 3, bottom panel) showed again a 
similar profile of luciferase activities than the previous -320 and -207 constructs, but with 
higher activities than the -207 series and lower activities than the -320 series, confirming the -
207/-112 silencer region and the dominant -320/-207 enhancer. 
All together, these data are consistent with binding of regulatory elements to PSIP1 promoter 
regions located between LEDGF/p75 and p52 TSS, thereby modulating their relative 
expression. 
 
Expression of LEDGF/p75 and p52 is mediated by the transcription factor Sp1.  
Analysis of the sequences surrounding LEDGF/p75 and p52 TSSs did not reveal any 
consensual TATA or TATA-like box sequence, thereby classifying PSIP1 promoter as 
TATA-less. TATA-less promoters are characterized by the presence of multiple TSSs, CpG 
 
 islands and Sp1 transcription factor binding sites 33. Alibaba2.1 (TRANSFAC) and TESS 
search tools were used to analyze LEDGF/p75 and p52 minimal promoter sequences and 
identify transcription factor binding sites. PSIP1 sequence analysis identified multiple 
putative Sp1 binding sites, characterized by GC-rich content, and consistent with TATA-less 
promoters (Figure 4a).  
To investigate the role of Sp1 in PSIP1 promoter activity, luciferase activity driven by 
LEDGF/p75 -723/+59 and p52 +140/+781 promoters was first assessed in presence or 
absence of mithramycin (Figure 4b, top panels). Mithramycin binds GC-rich motifs, and is 
widely used as an inhibitor of Sp1–DNA binding 34; 35. As expected for Sp1-bound promoters, 
mithramycin impaired luciferase expression driven by both LEDGF/p75 and p52 promoters, 
in a dose-dependent manner (Figure 4b, top panels). To confirm the involvement of Sp1 in 
PSIP1 promoter activity, luciferase activities were assessed in HEK cells expressing 
increasing amounts of the transcription factor Sp1 (Figure 4b, bottom panels). Increasing 
amounts of Sp1 were associated with increased luciferase activities, for both LEDGF/p75 and 
p52 promoter constructs. Increased luciferase activities also correlated with enhanced 
expression of endogenous LEDGF/p75 and p52 (Figure 4c), further arguing for a role of Sp1 
in modulating PSIP1 promoter activity. 
In order to investigate whether Sp1-mediated PSIP1 promoter regulation was due to a direct 
Sp1 binding to PSIP1 promoter sequences and not to an indirect effect, we performed 
chromatin immunoprecipitation (ChIP) with anti-Sp1 antibody followed by PCR 
amplification of -112/+59 PSIP1 promoter sequence. As shown in Figure 4d, anti-Sp1 ChIP 
specifically captured the -112/+59 LEDGF/p75 promoter sequence, which could be amplified 
by specific PCR. In contrast, no PSIP1-specific PCR amplification was detected when using a 
rabbit normal serum for ChIP or in presence of mithramycin, the Sp1-DNA binding inhibitor.  
All together, these data are consistent with a role of Sp1 in modulating PSIP1 transcription. 
 
  
Identification of two Sp1 binding sites in modulating LEDGF/p75 promoter activity.  
To identify more specifically which putative Sp1 binding sites are essential for Sp1 activity, 
mutagenesis was carried out on the -112/+59 region in order to reduce the GC content of these 
sequences (Figure 4a and Table 1) in the context of -723/+59 and tested for luciferase activity 
(Figure 5a).  
Mutations of site 2 (CATTACAAC for mSp1 site 2 instead of wt CATCCCCCC) and site 3 
(GATCACTACAC for mSp1 site 3 instead of wt GGTCGCGCCCC), individually or 
combined, reduced significantly LEDGF/p75 promoter activity whereas site 1 and the 
multiple sites 4 individually or in combination did not alter significantly luciferase activity 
(Figure 5a and supplementary figure S2).  
To further investigate the role of these Sp1 binding sites 2 and 3, luciferase activity was 
assessed in presence of increasing amounts of Sp1 (Figure 5b). As expected, increasing 
amounts of Sp1 stimulated LEDGF/p75 wt promoter activity and thus luciferase expression. 
In contrast, no similar stimulation was observed in presence of increasing amounts of Sp1 
when the PSIP1 promoter was mutated for one or two Sp1 binding sites (Figure 5b). 
Furthermore, transcript analysis by 5’ RLM-RACE showed that, in addition to lower 
transcript quantity, transcript quality was also affected, with transcription starting further 
upstream, in the -320/-207 enhancer region (data not shown). 
Thus, Sp1 overexpression required both wt Sp1 binding sites located at -72/-64 and -46/-36 of 
LEDGF/p75 promoter for complete activity. 
 
 DISCUSSION 
Although LEDGF/p75 has many implications in cell survival and has been involved in many 
diseases, such as cancer, psoriasis, autoimmunity and HIV, little is known about its expression 
regulation. Here, we reported for the first time key elements involved in PSIP1 gene 
regulation, more particularly regulation of the PSIP1/LEDGF/p75 splice variant.  
By 5’ RLM-RACE approach of endogenous LEDGF/p75 and p52 as well as luciferase 
constructs, we identified the transcription start site of LEDGF/p75 and p52 transcripts to be 
located at 36 bp and 64 bp downstream of the NCBI reference respectively, in our 
experimental system. Furthermore, RACE and RT-PCR experiments provided evidence that 
p52 transcripts initiated at p52 TSS but not at LEDGF/p75 TSS, suggesting that LEDGF/p75 
and p52 could be two overlapping genes with two distinct promoters that could impact on each 
other rather than two splice variants.  
Computational analysis of PSIP1 promoter revealed the absence of TATA box consensus. 
Consistent with TATA-less promoters, TSS sloppiness can be observed, as implied by the 
variety of PSIP1 mRNA sequences deposited to NCBI nucleotide sequence database 36; 37.  
Transcription of TATA-less promoters are mostly driven by the Sp1 transcription factor 38. 
Consistently, we identified putative Sp1 binding sites in both LEDGF/p75 and p52 promoters. 
Modulation of Sp1 activity by overexpression or using a Sp1–DNA binding inhibitor 
confirmed the role of Sp1 in regulating PSIP1 transcription. Further investigation of the 
essential -112/+59 region on the LEDGF/p75 promoter by mutagenesis revealed two 
functional Sp1 binding sites, sites 2 (-72/-64) and 3 (-46/-36). The impact on transcription was 
higher for the mutation on site 3 with a two-fold decrease of LEDGF/p75 promoter activity 
compared to the WT. Mutations on both sites 2 and 3 decreased at least 5 fold the LEDGF/p75 
promoter activity. However, mutation on both Sp1 binding sites did not totally abrogate 
 
 LEDGF/p75 promoter activity (in contrast to the deletion of the region -112/+59), suggesting 
that additional factors may be involved in transcription regulation.  
The nuclear protein Sp1 belongs to a growing family of transcription factors that modulate 
gene expression 39. Sp1 binds specifically to DNA and to the cofactor required for Sp1 (CRSP) 
complex in order to initiate transcription, via recruitment of TATA binding protein-associated 
factors 40. Sp1-mediated transcription has been implicated in the growth and metastasis of 
cancer cell lines 41, and has been shown to be overexpressed in tumor cells 42; 43. Similarly, and 
consistent with our data of Sp1-mediated transcription of PSIP1, several studies reported that 
LEDGF/p75 is overexpressed in cancer cells compared to normal tissue 5. Furthermore, in 
pancreatic cancer cells, Sp1 stimulates expression of the vascular endothelial growth factor 
(VEGF) 42; 44. Recently, LEDGF/p75 was shown to modulate the expression of VEGF 7; 45. Our 
data may suggest an additional and indirect mechanism of VEGF expression regulation, in 
which Sp1 increases LEDGF/p75 expression, which in turn stimulates VEGF expression.  
PSIP1 promoter contains two overlapping promoters, each driving the expression of PSIP1 
splice variants, LEDGF/p75 and its shorter isoform p52. Artificial dissociation of the 
overlapping LEDGF/p75 and p52 promoters identified a strong dominant enhancer in the -
320/-207 region and a silencer in the -207/-112 region affecting Sp1-mediated transcription of 
LEDGF/p75, and an enhancer in the +448/+609 region affecting p52 transcription (Figure 6). 
However, in vivo, the two promoters are tightly intertwined and impact each other, thus 
affecting the expression of both splice variants as observed in previous work 5 and in the 
present study, and keeping constant the uneven expression ratio between LEDGF/p75 and p52. 
Consistent with this model, the +339/+420 region was able to completely shut down the 
expression driven by LEDGF/p75 TSS specifically, effect that could be relieved by the 
+521/+659 region (that overlaps partially with the +448/+609 p52 enhancer). This +521/+659 
region was also able to increase ~2 fold LEDGF/p75 transcriptional activity, providing a 
 
 positive loop of regulation. In presence of the +659/+781 region surrounding the p52 TSS, the 
~2 fold enhancer effect induced by the +521/+659 region is inhibited. The detailed mechanism 
of action of these regulatory loops is not yet completely understood but might involve 
cooperation between Sp1 and other transcription factors bound on regulatory elements of the 
promoter. Direct action through transcription factor interactions and/or through chromatin 
rearrangement may explain the complex interplay between the two overlapping promoters of 
PSIP1 splice variants, thereby allowing fine regulation of LEDGF/p75 and p52 transcription.  
Further studies should provide additional details and help further understanding of the 
molecular mechanisms regulating LEDGF/p75 and p52 expression, thereby providing new 
therapeutic strategies to treat LEDGF/p75-related pathologies. 
This present study identified the first pieces of the complex mechanism of the LEDGF/p75 and 
p52 interplay regulation. Further studies should provide additional details and help further 
understanding these molecular mechanisms that should bring new strategies to modulate 
LEDGF/p75 and p52 expression for LEDGF/p75-related pathologies. 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
Cell culture, reagents and antibodies. 
HEK (human embryonic kidney) cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 2 mM glutamax (Invitrogen, CA, USA), 10% heat inactivated 
fetal calf serum and antibiotics (1% penicillin / streptomycin). SupT1 cells were cultivated in 
RPMI-1640 medium supplemented with 2 mM glutamax, 10% heat inactivated fetal calf serum 
and antibiotics (1% penicillin / streptomycin).  
Mithramycin (Sigma-Aldrich, MO, USA), a Sp1 binding inhibitor, was directly added to cell 
culture medium at final concentrations ranging from 50 nM to 800 nM.  
Antibodies used for western blot analyses included goat anti-Sp1 (PEP-2) antibody  (sc-59G; 
Santa Cruz Biotechnology, CA, USA), mouse anti-PSIP1 antibody recognizing both 
LEDGF/p75 and p52 proteins (clone 26; BD Biosciences, NJ, USA), mouse anti-α-tubulin 
antibody (clone B-5-1-2; Sigma-Aldrich, MO, USA), as well as horseradish peroxidase-
conjugated anti-mouse and anti-goat secondary antibodies (P0260 and P0160 respectively; 
DakoCytomation, Denmark). Working dilutions were 1/300, 1/300, 1/1000 respectively for the 
primary antibodies and 1/2000 for the secondary antibodies.  
 
5’ RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE). 
Total RNA was extracted using Illustra RNA Spin mini kit (GE Healthcare, UK) following 
manufacturer’s guidelines. 2 µg of total RNA were used for 5′ RLM-RACE using GeneRacer 
(Invitrogen, CA, USA), according to manufacturer’s instructions with some modifications 
specified hereafter. Briefly, 5′-uncapped RNAs (immature transcripts) were dephosphorylated 
by the calf intestinal phosphatase to avoid their subsequent contamination in the procedure. 
Subsequently, mature mRNAs were treated with Tobacco acid pyrophophatase for 5’ cap 
removal, ligated to the GeneRacer™ RNA oligo and reverse transcribed with the Superscript II 
 
 using a gene-specific 5’-biotinylated reverse primer (for LEDGF/p75 and p52: 5’-biotin-
CGAGCTGGCCAATGGGGATAACC-3’; for luciferase: 5’-biotin-
CGGTCCCGTCTTCGAGTGGGTAGAATGG -3’). Biotinylated cDNAs were diluted in 400 
µl of Bind and Wash 2X buffer (10 mM Tris-HCl pH7.5, 1mM EDTA, 2M NaCl) and 
incubated at 4°C for 1 hour with 400 µl streptavidin-coupled magnetic beads (Dynal, 
Invitrogen, CA, USA). After 3 washes with 500 μl of Bind and Wash 1X buffer, cDNAs 
coupled beads were resuspended in 30 μl of nuclease free water. A first PCR reaction was 
performed on 3 μl of bead-captured cDNAbeads with 2.5 U PfuTurbo™ polymerase 
(Stratagene, CA, USA), 600 nM GeneRacer™ 5’ forward primer (5’-
CGACUGGAGCACGAGGACACUGA-3’), 200 nM gene-specific reverse primer (5’-
CGAGCTGGCCAATGGGGATAACC-3’ for LEDGF/p75 and p52 or 5’-
CGGTCCCGTCTTCGAGTGGGTAGAATGG-3’ for luciferase), 200 μM each dNTP, in 50 µl 
final volume. PCR cycling conditions were: 5 min at 95°C, 35 cycles of 30 sec at 95°C-30 sec 
at 55°C – 5 min at 68°C, and a final 10 min at 68°C. 1 µl of this first PCR reaction was used 
for a nested PCR with 5 U Herculase2™ polymerase (Stratagene, CA, USA), 200 nM 
GeneRacer™ 5’ nested primer (5’-GGACACUGACAUGGACUGAAGGAGUA-3’), 200 nM 
gene-specific nested primer (5’-CATCTTGGCGAAGATGAGGTCTCC-3’ for LEDGF/p75 
and p52 or 5’-TTTTTTCTCGAGGTTTCGGGGGCGAGACCGGG-3’ for luciferase), 200 μM 
each dNTP, in 50 µl final volume. PCR cycling conditions were: 5 min at 95°C, 35 cycles of 30 
sec at 95°C-30 sec at 55°C – 2 min at 72°C, and a final 10 min at 72°C. PCR products were 
separated by gel electrophoresis and purified using Invisorb gel extraction kit (Invitek, GmbH). 
Purified PCR products were incubated with 5 U Taq DNA polymerase (Invitrogen, CA, USA ) 
at 72°C for 15 min, allowing the adjunction of a single deoxyadenosine (A) to the 3´ ends, 
before cloning into pCR4-TOPO TA vectors (TOPO TA Cloning Kit, Invitrogen, CA, USA ) 
and transformation into TOP10 bacteria according to manufacturer’s instructions. Plasmid 
 
 DNA was isolated from individual colonies and sequenced using the provided M13F and 
M13R primers. 
 
Construction of PSIP1 promoter truncations in firefly luciferase reporter vectors. 
PSIP1 promoter (-2043/+781 bp) was amplified by PCR using BAC clone RP11-211N10 
(BACPAC Resources, Children’s Hospital Oakland Research Institute) as template, with 
primers MA.pr-110 and MA.pr-124 (Table 1) and Herculase II Fusion DNA polymerase® 
(Stratagene, CA, USA) according to instructions, and subcloned into TOPO-blunt vector 
(Invitrogen, CA, USA). This plasmid was used as template for subsequent PCR reactions, 
allowing the construction of a collection of PSIP1 promoter truncations (table 1). PCR 
reactions were performed with Pfu Turbo polymerase® according to the manufacturer’s 
conditions and supplemented with 5% DMSO (Stratagene, CA, USA). All the primers used to 
generate the PSIP1 truncations were tailed with KpnI site (forward primers) or XhoI site 
(reverse primers). Upon gel purification with Invisorb gel extraction kit (Invitek, Germany), 
PCR products were digested with KpnI and XhoI (New England Biolabs, MA, USA), cleaned 
on PCRapace columns (Invitek, Germany) and inserted into the pGL4.10 basic vector 
(Promega, Madison, WI), upstream of the firefly luciferase coding sequence. All the 
constructions were checked by restriction analysis and sequencing.  
 
Determination of promoter activity by dual-luciferase reporter assay. 
HEK cells (100,000 cells) were plated in 500 μl of culture medium in a 24-well plate and 
allowed to grow for one day to reach approximately 50-60% confluence for transfection. DNA 
transfection (1 µg) was performed using the cationic polymer jetPEI™ reagent according to the 
manufacturer’s procedure (Polyplus-transfection, France). Firefly luciferase reporter constructs, 
driven by PSIP1 promoter fragments (250 ng), were co-transfected with 5 ng of Renilla 
 
 luciferase reporter construct (pGL4.74), driven by the thymidine kinase promoter (Promega, 
Madison, WI) to normalize for transfection efficiency. An empty vector, pCI, was added to the 
transfection mix to reach the 1 µg total DNA required for optimal transfection efficiency.  
For inhibition assays, mithramicin (0-800 nM) was added to the cells 1h prior transfection and 
then kept throughout the experiment.  
For Sp1 overexpression assays, increasing amounts of pCMV-Sp1 encoding plasmid (0-750 
ng) was added to the luciferase transfection mixture, and completed to 1 µg total DNA with 
pCI as described above.  
Cells were collected 40h post-transfection, lysed in 150 μl of 1X Passive Lysis Buffer for 10 
min at room temperature, and frozen at -20°C. Luminescence intensity was measured by dual 
luciferase assay using 5 µl cell lysate and according to manufacturer’s recommandations 
(Promega, Madison, WI). Briefly, firefly luciferase activity was first measured by adding 25μl 
LARII reagent (firefly luciferase substrate), followed by the adjunction of 25 μl of Stop&Glo 
reagent, allowing for measurement of Renilla luciferase activity. Luminescence intensity, 
reflecting luciferase activity, was measured as relative light units (RLU) with the Lumat LB 
9507 luminometer (Berthold technologies, Germany). 
PSIP1 promoter activity (i.e. firefly luciferase activity) was normalized by the transfection 
efficiency (i.e. Renilla luciferase activity). The empty pGL4.10- vector (without promoter) was 
included in all experiments to determine the background level of firefly luciferase activity. 
PSIP1 promoter activity was graphed as fold activity above background, and was calculated as 
following: (ratio PSIP1 firefly/renilla) / (ratio pGL4.10 firefly/renilla), unless specified 
otherwise. 
For experiments with Sp1 overexpression, normalizations were performed by total protein 
concentration (Pierce® BCA Protein Assay Kit; Thermo scientific, MA, USA). 25 μl of sample 
diluted in 0.1X PBS (as recommended by the manufacturer; 
 
 http://www.promega.com/enotes/applications/ap0047_tabs.htm) was used for the assay. 
Measured RLU of each sample was divided with the background level (firefly luciferase 
activity of pGL4.10 / total proteins concentration of pGL4.10-transfected cells).  
 
Detection of LEDGF/p75 transcripts by RT-PCR. 
Total RNA from HEK cells (5x106 cells) was extracted using Illustra RNAspin mini RNA 
isolation kit (GE Healthcare, UK), followed by selection of polyA+ RNA using OligoTex 
(Qiagen) according to manufacturers’ instructions. Reverse transcription was performed using 
150 ng polyA+ RNA, in presence of 500 nM LEDGF/p75 or p52 specific 3’ primers, using the 
High Fidelity cDNA synthesis kit (Applied Biosystems), followed by standard PCR (HotStar 
Taq master mix, Qiagen) performed with specific primers as described in Figure 1d. 
 
Site-directed mutagenesis of Sp1 putative binding sites.  
The plasmid pGL4.10 containing the full length PSIP1 promoter (i.e. from -2043 to +781 bp) 
was used as template for site-directed mutagenesis. Mutations of putative Sp1 binding sites 
were performed by GC content modification. Briefly, mutations in each putative Sp1 binding 
site were performed by PCR using 3.5 U Pfu Turbo polymerase®, 5% DMSO, 200 μM each 
dNTP and 200nM of each primer. Primers MA.pr-280 and MA.pr-281 were used for the 
mutagenesis of Sp1 site 1, MA.pr-282 and MA.pr-283 for Sp1 site 2, MA.pr-284 and MA.pr-
285 for Sp1 site 3, and MA.pr-365 and MA.pr-366 for Sp1 site 4 (Table 1). PCR cycling 
conditions were 1 cycle at 95°C for 2 min, 18 cycles at 95°C for 30 sec55°C for 30 sec-68°C 
for 10 min, and 1 cycle at 68°C for an additional elongation time of 10 min. Upon 
amplification, PCR reactions were supplemented with 10 U DpnI and incubated at 37°C for 1h 
to digest the methylated parental plasmid (template), and finally transformed in XL1-blue 
 
 supercompetent cells (Stratagene, CA, USA). Mutagenesis efficiency was checked by 
sequence analysis. 
 
Western blots analysis. 
30 µg of total proteins in PLB 1X were mixed with GeBa sample buffer (Gene Bio-
Application, Israel)) and heated for 5 min at 95°C. Samples and the Color Plus™ prestained 
protein ladder (New England Biolabs, MA, USA) were separated by electrophoresis using pre-
cast 8-16% polyacrylamide gel (Gene Bio-Application, Israel) for 1h at 160V and transferred 
onto nitrocellulose membrane (Whatman, Germany) for 1h at 400 mA in TBT-methanol buffer 
(1.9 M glycine, 0.25 M Tris, 20% methanol, pH 8.6). Immunoblotting was performed using 
the SNAP-i.d. protein detection system (allowing solutions to pass through the membranes by 
vacuum aspiration), according to the manufacturer’s recommendations (Merck-Millipore, 
Billerica, MA). Briefly, pre-wet membranes were blocked with 15 ml of 0.1% non-fat milk 
solution , incubated for  10 min at room temperature in primary antibody diluted in 0.1% non-
fat milk, followed by three washes with  PBS 0.1% Tween®, incubated similarly with  the 
secondary antibody. The membrane was incubated with the LiteAblot chemiluminescent 
substrate (Euroclone, Italy) for 2 mins and revealed on autoradiographic Amersham 
hyperfilm™ MP (GE Healthcare, UK).  
 
Chromatin immunoprecipitation (ChIP). 
Chromatin immunoprecipitation was performed using the MAGnify chromatin 
immunoprecipitation system (Invitrogen, CA, USA), according to the manufacturer’s protocol 
with some modifications. Briefly, HEK cells (2x106) were transfected with the firefly luciferase 
reporter plasmid containing the PSIP1 promoter from -723 bp to +59 bp, with or without 
mithramycin treatment (200 nM). At 30h post-transfection, cells were crosslinked in 1% final 
 
 formaldehyde for 10 min at 37°C, and the reaction was stopped by adding 1.25M glycine for 5 
min at 4°C. Crosslinked cells were washed twice in ice cold PBS and collected by 
centrifugation for 5 min at 700g. The cell pellet was resuspended with 500 µl SDS lysis buffer 
(1% SDS, 10mM EDTA, 50 mM Tris pH 8.1), supplemented with protease inhibitors (protease 
inhibitor cocktail P8340; Sigma-Aldrich, St Louis, MO), and incubated on ice for 10 min. Cell 
lysates (100 μl) were  diluted 5 fold in PBS and sonicated using a Soniprep 150 (N.Zivy & Co, 
Switzerland) for 5 cycles of 10 sec at maximum potency followed by 1 min incubation at 4°C), 
generating chromatin sheared fragments between  250 and 1500 bp. For each condition, 2μg of 
ChIP-grade Sp1 antibody (Abcam, UK) or normal rabbit IgG (provided in the kit as control) 
were mixed with 200µl Dilution Buffer allowed to bind to protein A and G conjugated 
magnetic beads, and used to immunoprecipitate chromatin for 2h at 4°C. After several washes, 
reverse crosslink and purification, immunoprecipitated DNA (2μl) was amplified using 400nM 
MA.pr-121 and MA.pr-130 (Table 1) and 22 μl AccuPrime™ Pfx SuperMix (Invitrogen, CA, 
USA). As controls, DNA inputs (before ChIP) were amplified similarly. The PCR reaction was 
performed under the following conditions: 1 cycle 95°C for 5 min, 30 cycles at 95°C 30sec, 
55°C 30sec and 68°C 1min, and 1 cycle 68°C 10 min. PCR amplification was checked by gel 
electrophoresis using 5μl of the PCR reaction. 
 
Statistical analysis. 
Data are presented as mean ± SEM. Differences between groups were assessed by two-sided 
student t- test. * = p value ≤ 0.1; ** = p value ≤ 0.01; *** = p value ≤ 0.001. One way ANOVA 
statistical analysis was performed for experiments using mithramycin and Sp1 overexpression. 
All statistical analyses were performed using GraphPad software Prism™ v5 (GraphPad 
Software, CA, USA). 
 
 
 Bioinformatic analysis of PSIP1 promoter sequence. 
To identify putative transcription factors binding sites on LEDGF/p75 (-112/+59 bp) and p52 
(+609/+781 bp) core promoters, the software Alibaba 2.1 (http://www.gene-
regulation.com/pub/programs/alibaba2/index.html) was used to screen the TRANSFAC 4.0 
database. The analyses were carried out under strict parameters (matrix conservation 80% and 
matrix width of 10 bp).  
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 TABLE AND FIGURE LEGENDS 
 
Table 1. List of primers used in this study. 
 
Figure 1. Identification of PSIP1 transcription start sites (TSSs) using 5’- RNA Ligase 
Mediated Rapid Amplification of cDNA Ends (5’ RLM-RACE). a) Schematic 
representation of PSIP1 genomic DNA (gDNA), with the two major RNA splice variants and 
encoded proteins. Exons were represented with boxes according to their length and their 
positions. b) Scheme of  5’RLM-RACE amplification on HEK cell total RNA (right panel). 
Reverse transcription and first PCR were performed with  primers 1 (GeneRacer™ 5’ primer) 
and 1’ (gene specific primer); followed by nested PCR with primers 2  and 2’.  PCR products 
were separated by gel electrophoresis (left panel), highlighting the two major variants, 
LEDGF/p75 and p52. c) Genomic DNA sequence of PSIP1 (as deposited in Genbank), 
showing the TSS identified in our experimental system: LEDGF/p75 TSS (+1) and p52 TSS 
(+745), respectively at 36 bp and 64 bp downstream of the annotated NCBI TSS (triangle). 
Additional minor TSS positions are marked with arrows. The underlined sequence corresponds 
to the first intron of the PSIP1 gene (+154/+640) and asterisks to the start codon of both 
LEDGF/p75 and p52. d) Specific RT-PCR of LEDGF/p75 and p52 transcripts. Reverse 
transcription of endogenous LEDGF/p75 (lanes 1 and 2) and p52 (lanes 3 and 4) transcripts 
was performed using specific 3’ primers (right scheme) and used for PCR with p75-
5’/Exon2a/2c-PSIP1 (lane 1), ATG-PSIP1/p75-3’ (lane 2), p75-5’/Exon2a/2c-PSIP1 (lane 3),  
ATG-PSIP1/p52-3’ (lane 4). 
 
Figure 2. Identification of PSIP1 promoter regulatory elements.  
 
 a) Schematic representation of the PSIP1 promoter showing the progressive 5’ end truncations 
used to identify PSIP1 promoter regulatory elements . b) Isolation of the functional PSIP1 
promoter. Luciferase activity driven by 5’ end PSIP1 promoter truncations at -2048, -1195, -
723 and -207. c) Comparison of the -723/+59 and +140/+781 PSIP1 regions showed that 
LEDGF/p75 (~59 fold) and p52 (~ 5 fold) promoters displayed additive transcription activity. 
As control, minimal promoter activity containing consensual TATA box was measured in 
luciferase assay (blue rectangle). d) Left graph: Luciferase activity driven by finer progressive 
5’ end truncations of the LEDGF/p75 promoter. Right graph: luciferase activity driven by a 
minimal TATA box in presence or absence of the upstream -320/-207 enhancer region.. e) 
Identification of p52 promoter regulatory regions.  
PSIP1 promoter activity was graphed as fold activity above background determined by the 
empty vector (pGL4.10), and was calculated as: RLU PSIP1 construct / RLU background. 
Data presented as mean ± SEM. Differences between groups were assessed by student t- test. * 
= p value ≤ 0.1; ** = p value ≤ 0.01; *** = p value ≤ 0.001. 
 
Figure 3. Crosstalk between LEDGF/p75 and p52 promoter activities. 
Analysis of luciferase activity with 3’ progressive deletions starting at -320 (top panel), -207 
(middle panel) and -112 (bottom panel). PSIP1 promoter activity was graphed as fold activity 
above background (determined by luciferase activity driven by the empty pGL4.10 vector), 
and was calculated as following: RLU of the PSIP1 construction / RLU of the background. 
Data are presented as mean ± SEM.  
 
Figure 4. PSIP1 transcription is modulated by the Sp1 transcription factor.  
a) Mapping of putative Sp1 binding sites on PSIP1 promoter using Alibaba2.1 querying the 
TRANSFAC database  b) Effect of the Sp1 binding site inhibitor mithramycin (top graphs) 
 
 and Sp1 overexpression (bottom graphs) on LEDGF/p75 (left graphs) and p52 (right graphs) 
promoters.  
Firefly luciferase activity was normalized with the total protein concentration and then 
compared with the normaliyed background level (firefly luciferase activity of pGL4.10 / total 
protein concentration of pGL4.10-transfected cells). Data are presented as mean ± SEM. 
Differences between groups were assessed by ANOVA test. (mithramycin assay: n=6, p value 
≤ 0.0001; Sp1 overexpression assay: n=5, p value ≤ 0.001). c) Endogenous levels of 
LEDGF/p75 and p52 were modulated by the transcription factor Sp1. Western blot analysis of 
cells transfected with increasing amounts of Sp1 expression vector, for Sp1 expression (top 
panel), LEDGF/p75 and p52 expression (middle panel) and tubulin expression as loading 
control (bottom panel). d) Sp1 binding to LEDGF/p75 promoter was investigated by 
chromatin immunoprecipitation followed by specific PCR. ChIP was performed using anti-Sp1 
or normal rabbit IgG antibody (negative control). The immunoprecipitated DNA was 
amplified with primers specific for LEDGF/p75 minimal promoter (-112/+59). To check for 
ChIP specificity, 200 nM of the Sp1 binding inhibitor mithramycin was added. Amplification 
of the LEDGF/p75 minimal promoter (-112bp/+59) was performed by PCR. The sheared and 
crosslinked chromatin prior to ChIP was used as a positive control for PCR (input). (*) 
corresponded to the primers used in the PCR reaction.  
 
Figure 5. Sp1 binding sites -72/-64 and -46/-36 are responsible for Sp1-mediated PSIP1 
transcription regulation. 
a) Mutagenesis of putative Sp1 sites of LEDGF/p75 promoter, individually or in combination. 
Putative Sp1 site 1 corresponds to the -101/-91 region of the promoter, putative Sp1 site 2 to -
72/-64 and putative Sp1 site 3 to-46/-36 (see also Figure 4a). PSIP1 promoter activity  was 
graphed as fold activity above background determined by the empty vector (pGL4.10), and 
 
 was calculated as following: RLU of the PSIP1 construct / RLU of the background. Data are 
presented as mean ± SEM. Differences between groups were assessed by students t- test. ** = 
p value ≤ 0.01. b) Effect of Sp1 overexpression on promoter constructs with mutated Sp1 
binding sites. WT promoter -723/+59 containing the LEDGF/p75 TSS was stimulated with 
increasing amounts of Sp1, whereas Sp1 mutated promoters did not reveal any dose-dependent 
activity in presence of Sp1 overexpression. Western blots (bottom panels) were performed 
using anti-Sp1 and anti-tubulin to check Sp1 overexpression in all the samples tested in 
luciferase assay. 
 
Figure 6. Model of PSIP1 gene regulation. Grey boxes represent enhancers of the 
downstream TSS. The red box indicates the upstream silencer of LEDGF/p75 TSS. Green 
lines indicate mechanisms decreasing LEDGF/p75 transcription. Blue lines show mechanisms 
resulting in an increase of LEDGF/p75 promoter activity. Arrows indicate stimulation of the 
regulatory element whereas bars show inhibition of the regulatory element. The Sp1 
transcription factor is represented with the black hexagon which can bind the functional 
binding sites -72/-64 and -46/-36 to induce transcription of the LEDGF/p75 promoter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
name sequence position Used for 
MA-pr 110 TTTTTTGGTACCGCAGCAGGAGCTAAGTATGG -2043/-2023 5’ deletions of LEDGF/p75 promoter  
MA.pr-111 TTTTTTGGTACCTTGCTCCACTTGGAACTCTC -1195/-1175 5’ deletions of LEDGF/p75 promoter 
MA.pr-115 TTTTTTGGTACCCCTGTCATTGTTTTCTACC -723/-704 5’ deletions of LEDGF/p75 promoter 
MA.pr-116 TTTTTTGGTACCATACTACAATTTCAAGGAAAAGG -618/-595 5’ deletions of LEDGF/p75 promoter 
MA.pr-117 TTTTTTGGTACCCCGCCGCATGCTCCAATTTCATC -538/-515 5’ deletions of LEDGF/p75 promoter 
MA.pr-118 TTTTTTGGTACCAATCTTTACTGCCACTTTCTCC -420/-398 5’ deletions of LEDGF/p75 promoter 
MA.pr-119 TTTTTTGGTACCGCCTTTTACATACAGTACAC -320/-300 5’and 3’ deletions of LEDGF/p75 
promoter and effect of the +59/+659 
region 
MA.pr-120 TTTTTTGGTACCTTTCGCCCAGTCCTTTCTTC -207/-187 5’ deletions of LEDGF/p75 promoter 
MA-pr 121  TTTTTTGGTACCAATCCGCTTCGGAGCCACAC -112/-92 5’ deletions of LEDGF/p75 promoter 
MA.pr-122 TTTTTTGGTACCCAGTGCTAGCGGGCGCCGAG -37/-17 5’ deletions of LEDGF/p75 promoter 
MA.pr-123 TTTTTTGGTACCTTCGCTTTAACCGCCCTCGGTG +609/+631 5’ deletions of p52 promoter 
MA.pr-124 TTTTTTCTCGAGGTTTCGGGGGCGAGACCGGG +781/+761 5’ deletions of p52 promoter and 3’ 
deletion of the LEDGF/p75 promoter 
MA.pr-127 TTTTTTCTCGAGAAAGGCAGGGATTCCGAGAAG +339/+318 3’ deletions of LEDGF/p75 promoter 
MA.pr-128 TTTTTTCTCGAGCCCGGGCGGGCCGCGTCCAC +240/+220 3’ deletions of LEDGF/p75 promoter 
MA.pr-129 TTTTTTCTCGAGGGGCGCCGACGCTGCGGTTG +140/+120 3’ deletions of LEDGF/p75 promoter 
MA.pr-130 TTTTTTCTCGAGCGTCTCAACGGCTCGGAATC +59/+39 5’ deletions of LEDGF/p75 promoter 
MA.pr-226 TTTTTTCTCGAGCGGGCGGGGGAGGATGCCTCGG +659/+647 Effect of the +59/+659 region 
MA.pr-265 TTTTTTGGTACCCGCGGCCCCGGCAGGTGAGC +140/+160 5’ deletions of p52 promoter 
MA.pr-266 TTTTTTGGTACCGGCCCGCCCGGGAGCCGAGG +229/+249 5’ deletions of p52 promoter 
MA.pr-267 TTTTTTGGTACCTCCCATGCACCCCCTCCCTTTTG +345/+368 5’ deletions of p52 promoter 
MA.pr-268 TTTTTTGGTACCTCAGGTGGTGGCGTCTCTTCGGTGG +448/+473 5’ deletions of p52 promoter 
MA.pr-269 TTTTTTGGTACCCTCCCACCCCCACCCGCCGGTTCC +548/+572 5’ deletions of p52 promoter 
MA.pr-270 TTTTTTCTCGAGGCCCGTCTGCCCGCCCCATCTTTC +420/+396 3’ deletions of LEDGF/p75 promoter 
MA.pr-271 TTTTTTCTCGAGCTCCCCCGCCAGTGCGCTGCCTCCG +521/+496 3’ deletions of LEDGF/p75 promoter 
MA.pr-280 ATCCGCTTCGTAGTAACATAGCTTCGCCGGGTGC -111/-80 Sp1 binding site mutagenesis (site 1) 
MA.pr-281 GGCGAAGCTATGTTACTACGAAGCGGATTTTCTGG -119/-86 Sp1 binding site mutagenesis (site 1) 
MA.pr-282 CGGGTGCTGCAACATTACAACTCTCTCGGTAAAC -86/-53 Sp1 binding site mutagenesis (site 2) 
MA.pr-283 ACCGAGAGAGTTGTAATGTTGCAGCACCCGGCGAAGC -92/-56 Sp1 binding site mutagenesis (site 2) 
MA.pr-284 TAAACAGTTGATCACTACACAGTGCTAGCGGGC -56/-32 Sp1 binding site mutagenesis (site 3) 
MA.pr-285 GCACTGTGTAGTGATCAACTGTTTACCGAGAGAGG -66/-37 Sp1 binding site mutagenesis (site 3) 
MA.pr-346 CAGTGCTAGCGGGCGCCGATAGTGATCTGCG -37/-7 Sp1 binding site mutagenesis (site 4.1) 
MA.pr-347 GCGCAGATCACTATCGGCGCCCGCTAGCACTG -6/-37 Sp1 binding site mutagenesis (site 4.1) 
MA.pr-348 CGAGCGGGAGCCTCTCAGAAGTAGCGCAGC -21/+10 Sp1 binding site mutagenesis (site 4.2) 
MA.pr-349 GTAGCTGCGCTACTTCTGAGAGGCTCCCGCTCG +13/-21 Sp1 binding site mutagenesis (site 4.2) 
MA.pr-350 CGATAGTGATCTGCGCGGGAGCAGCGCAGC -21/-9 Sp1 binding site mutagenesis (site 4.3) 
MA.pr-351 GTAGCTGCGCTGCTCCCGCGCAGATCACTATCG -13/-21 Sp1 binding site mutagenesis (site 4.3) 
MA.pr-365 AGTGCTATCATGTGACGATAGTGATCTTCTCAGAAGTAGCGCAGC -36/+10 Sp1 binding site mutagenesis (full site 4) 
MA.pr-366 GCTGCGCTACTTCTGAGAAGATCACTATCGTCACATGATAGCACT +10/-36 Sp1 binding site mutagenesis (full site 4) 
Bold: mismatch for mutagenesis of Sp1 binding sites  
Underlined: restriction site of XhoI or KpnI 
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Figure S2. Mutagenesis of the putative Sp1 binding site 4. Computational analysis of the promoter showed three 
putative overlapping Sp1 binding sites (named 4.1, 4-2 and 4-3) in the region -28/+4 encompassing the 
LEDGF/p75 TSS. Individual or combined mutations in Sp1 site 4 did not affect LEDGF/p75 promoter activity. 
PSIP1 promoter activity was graphed as fold activity above background determined by the empty vector 
(pGL4.10), and was calculated as following: RLU of the PSIP1 construction / RLU of the background
S1) TSS LEDGF/p75
ATG
TSS p52intron
luc2
-2043 -1195 -723 -320 -207 +140-112 -37 +59
Sp1
+781+652 +731
Sp1
+35 +912
Figure S1. Identification of luciferase transcripts starting at TSS p75 (+1). PolyA+ RNA was extracted from HEK 
cells 40 h post transfection with luciferase constructs driven by diverse PSIP1 promoter regions. Reverse trans-
cription was performed using 150 ng of polyA+ RNA, hexamers and MultiScribe RT (Applied Biosystem). PCR 
was performed using primers that amplified the +35/+912 product, and ß-actin as control. Luciferase assay was 
performed at 40h post transfection as described in the Materials and Methods section.
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LEDGF/p75 TATA-less promoter is driven by the transcription factor Sp1 
 
Highlights 
 
> LEDGF/p75 is involved in many cellular processes and diseases 
> LEDGF/p75 gene regulation was analyzed by luciferase assay 
> LEDGF/p75 is driven by a TATA-less promoter 
> Promoter regions necessary for LEDGF/p75 regulation were also identified 
> Sp1 is the key regulator for LEDGF/p75 expression 
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